CompletedNot Applicable

RASi for Preventing Postoperative Recurrence of Stage II/III Colon Cancer

China2,640 participantsStarted 2012-01-04

Plain-language summary

The goal of this retrospective cohort study is to learn about the long-term effects of renin-angiotensin system inhibitors (RASi) in preventing patients with hypertension and stage II/III colon cancer from recurrence and metastases after radical resection. The main question it aims to answer is: Does RASi improve the 3-year disease-free survival of patients with hypertension and stage II/III colon cancer after surgery? Participants with hypertension and already having radical resection of stage II/III colon cancer will be followed up for 3 years.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Inferior tumor edge \> 15 cm from anal verge;
✓. Received radical resection of primary tumor;
✓. Pathological proved stage II or stage III adenocarcinoma;
✓. No evidence of distant metastases at time of surgery (including pelvis, peritoneum, liver, lung, brain, bone, distant lymph node, etc), according to ultrasound, CT, MRI, PET-CT, intraoperative exploration, etc;
✓. Combined with hypertension at time of surgery;
✓. No other malignancies in medical history except adequately treated basocellular carcinoma of the skin or in situ carcinoma of the cervix uteri;
✓. Informed consent.

Exclusion criteria

✕. Emergency surgery for acute intestinal obstruction, bleeding, perforation, etc;
✕. Multiple primary colorectal cancer;
✕. Hereditary colorectal cancer (familial adenomatosis polyposis, Lynch Syndrome, etc.);
✕. Co-existent inflammatory bowel disease;
✕. Pregnancy or lactation;
✕. Received any of preoperative anti-cancer treatment.

What they're measuring

3-year disease-free survival

Timeframe: 3 years after surgery

Trial details

NCT IDNCT07012538

SponsorFudan University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-12-30

View on ClinicalTrials.gov More Colon Cancer (Stage II &Amp;Amp; III) trials